Adherence to immunomodulatory drugs in patients with multiple myeloma.

Fiche publication


Date publication

janvier 2019

Journal

PloS one

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis, Dr CHRETIEN Marie-Lorraine


Tous les auteurs :
Cransac A, Aho S, Chretien ML, Giroud M, Caillot D, Boulin M

Résumé

Immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide; IMID) are widely used in the treatment of multiple myeloma patients. To date, few data are available on IMID adherence in multiple myeloma patients. The aim of our study was to evaluate IMID adherence and to compare two indirect methods to measure IMID adherence in multiple myeloma patients: a specific questionnaire and the medication possession ratio (MPR). Another aim was to explore this specific questionnaire for the assessment of IMID adherence in multiple myeloma patients.

Référence

PLoS ONE. 2019 ;14(3):e0214446